These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
193 related items for PubMed ID: 17680819
1. Central mechanisms of controlled-release metoprolol in migraine: a double-blind, placebo-controlled study. Siniatchkin M, Andrasik F, Kropp P, Niederberger U, Strenge H, Averkina N, Lindner V, Stephani U, Gerber WD. Cephalalgia; 2007 Sep; 27(9):1024-32. PubMed ID: 17680819 [Abstract] [Full Text] [Related]
3. Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment? Schellenberg R, Lichtenthal A, Wöhling H, Graf C, Brixius K. Headache; 2008 Jan; 48(1):118-25. PubMed ID: 18184294 [Abstract] [Full Text] [Related]
4. [Prevention of migraine using bisoprolol. Results of a double-blind study versus metoprolol]. Wörz R, Reinhardt-Benmalek B, Föh M, Grotemeyer KH, Scharafinski HW. Fortschr Med; 1992 May 20; 110(14):268-72. PubMed ID: 1351025 [Abstract] [Full Text] [Related]
5. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Cady R, Schreiber C. Headache; 2008 Jun 20; 48(6):900-13. PubMed ID: 18047501 [Abstract] [Full Text] [Related]
6. Central effects of drugs used in migraine prophylaxis evaluated by visual evoked potentials. Diener HC, Scholz E, Dichgans J, Gerber WD, Jäck A, Bille A, Niederberger U. Ann Neurol; 1989 Feb 20; 25(2):125-30. PubMed ID: 2645824 [Abstract] [Full Text] [Related]
7. [Beta blockers in migraine prophylaxis]. Shimizu T. Brain Nerve; 2009 Oct 20; 61(10):1125-30. PubMed ID: 19882938 [Abstract] [Full Text] [Related]
8. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Shuhendler AJ, Lee S, Siu M, Ondovcik S, Lam K, Alabdullatif A, Zhang X, Machado M, Einarson TR. Pharmacotherapy; 2009 Jul 20; 29(7):784-91. PubMed ID: 19558252 [Abstract] [Full Text] [Related]
9. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, Mills JG, Tonabersat TON-01-05 Study Group. Cephalalgia; 2009 Jul 20; 29(7):742-50. PubMed ID: 19222510 [Abstract] [Full Text] [Related]
11. The calcium channel blocker felodipine attenuates the positive hemodynamic effects of the beta-blocker metoprolol in severe dilated cardiomyopathy--a prospective, randomized, double-blind and placebo-controlled study with invasive hemodynamic assessment. Braun M, Edelmann F, Knapp M, Schön S, Schwencke C, Simonis G, Borst M, Weinbrenner C, Strasser RH. Int J Cardiol; 2009 Feb 20; 132(2):248-56. PubMed ID: 18579230 [Abstract] [Full Text] [Related]
14. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial. Cady RK, Mathew N, Diener HC, Hu P, Haas M, Novak GP, Study Group. Headache; 2009 Feb 20; 49(2):216-26. PubMed ID: 19222595 [Abstract] [Full Text] [Related]
16. Effects of topiramate and levetiracetam vs placebo on habituation of contingent negative variation in migraine patients. de Tommaso M, Guido M, Sardaro M, Serpino C, Vecchio E, De Stefano G, Di Claudio T, Specchio LM, Livrea P. Neurosci Lett; 2008 Sep 12; 442(2):81-5. PubMed ID: 18620023 [Abstract] [Full Text] [Related]
17. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Aurora SK, Rozen TD, Kori SH, Shrewsbury SB. Headache; 2009 Jun 12; 49(6):826-37. PubMed ID: 19545249 [Abstract] [Full Text] [Related]
19. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Rao BS, Das DG, Taraknath VR, Sarma Y. Neurol India; 2000 Sep 12; 48(3):223-6. PubMed ID: 11025624 [Abstract] [Full Text] [Related]